SEC Form 4

FORM 4

obligations may continue. See

Instruction 1(b)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average	ourden								

hours per response

0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Check this box if no longer subject to Section 16. Form 4 or Form 5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Perfetti Riccardo		on*	2. Issuer Name and Ticker or Trading Symbol <u>Applied Therapeutics Inc.</u> [APLT]	(Check	tionship of Reporting Per all applicable) Director Officer (give title	rson(s) to Issuer 10% Owner Other (specify
1	Last) (First) (Middle) C/O APPLIED THERAPEUTICS, INC. 545 5TH AVENUE, SUITE 1400		3. Date of Earliest Transaction (Month/Day/Year) 01/19/2021	X	below) Chief Medical	below)
(Street) NEW YORK (City)	NY (State)	10017 (Zip)	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indiv Line) X	idual or Joint/Group Filin Form filed by One Rep Form filed by More tha Person	orting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transa Code (8)				5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
			Code V		Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(1150.4)		
Common Stock	01/19/2021		М		465(1)	A	\$1.44	465	D			
Common Stock	01/19/2021		S		465(2)	D	\$21.83 ⁽³⁾	0	D			
Common Stock	01/20/2021		М		465(1)	A	\$1.44	465	D			
Common Stock	01/20/2021		S		465(2)	D	\$21.08(4)	0	D			
Common Stock	01/21/2021		М		465(1)	A	\$1.44	465	D			
Common Stock	01/21/2021		S		465(2)	D	\$20 .3 ⁽⁵⁾	0	D			

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		of		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (Right to Buy)	\$1.44	01/19/2021		М			465 ⁽¹⁾	(6)	12/16/2028	Common Stock	465 ⁽¹⁾	\$0.00	189,469	D	
Stock Option (Right to Buy	\$1.44	01/20/2021		М			465 ⁽¹⁾	(6)	12/16/2028	Common Stock	465(1)	\$0.00	189,004	D	
Stock Option (Right to Buy	\$1.44	01/21/2021		М			465 ⁽¹⁾	(6)	12/16/2028	Common Stock	465(1)	\$ 0.00	189,539	D	

Explanation of Responses:

1. Compensatory options granted under Applied Therapeutics, Inc.'s 2016 Equity Incentive Plan, exercised automatically pursuant to the reporting person's written trading plan previously entered into on

September 16, 2020, providing for the sale of shares underlying compensatory options in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

2. Automatic sales made pursuant to the reporting person's pre-existing written trading plan, providing for the sale of shares underlying compensatory options in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. 3. Weighted average price. These shares were sold in multiple transactions at prices ranging from \$21,6100 to \$22,1900 inclusive. The reporting person undertakes to provide the issuer, any security holder of

the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above 4. Weighted average price. These shares were sold in multiple transactions at prices ranging from \$20,7500 to \$21,7100 inclusive. The reporting person undertakes to provide the issuer, any security holder of

the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above 5. Weighted average price. These shares were sold in multiple transactions at prices ranging from \$20,1200 to \$20,4800 inclusive. The reporting person undertakes to provide the issuer, any security holder of

the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above 6. Thirty-three percent (33%) of the shares subject to the option vested on August 27, 2018, and one twenty-fourth (1/24th) of the remaining shares subject to the Option vested or shall vest each month thereafter, subject to Reporting Person continuing to provide service through each such date

Remarks:

/s/ Shoshana Shendelman,

01/21/2021

Attorney-in-Fact ** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

Date

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.